T-Therapeutics, a UK-based biotechnology company focused on developing next-generation T cell receptor (TCR) therapeutics for cancer and autoimmune diseases, has announced the expansion of its Series A financing, securing an…
UK: T-Therapeutics’ Series A expanded to total of US$91m
…
…






